Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CD74 | P04233 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16101681 | 0.90 | P2RX4 (0.52) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL18329012 | 0.86 | P2RX4 (0.52) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL16131562 | 0.78 | P2RX4 (0.52) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL16101686 | 0.75 | MEN1 (0.54) | P2RX4ALDH1A1MAPTHPGDPOLB | |
| SCHEMBL16131512 | 0.74 | P2RX4 (0.47) | P2RX4ALDH1A1SMPD1SMN1; SMN2 | |
| SCHEMBL16131524 | 0.74 | KDM4E (0.51) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL2860677 | 0.73 | P2RX4 (0.68) | P2RX4ALDH1A1TP53POLBMEN1 | |
| SCHEMBL16099478 | 0.69 | POLB (0.51) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL31667148 | 0.69 | POLB (0.54) | P2RX4ALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL14160793 | 0.69 | P2RX4 (1.00) | P2RX4ALDH1A1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2014153055-A2 | COMPOUNDS AND METHODS FOR TREATING CANCERS | HEALTH RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | P2RX4 4435/4885ALDH1A1 145/4885MAPT 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.